PrecisCa
PrecisCa supports patients, their caregivers, and health care providers at every step of their cancer journeys from diagnosis to remission, with up-to-date education on the latest advancements in cancer care and access to leading specialists to analyze patient scenarios
Breast
PrecisCa
Expert Panel Case Discussion: 59 y/o Woman With Stage IV ER/PR+ HER2- IDC of Left Breast With Lung Metastasis
FEATURING
Lesley Wu,
Naomi Dempsey,
Joyce O'Shaughnessy,
Reshma L. Mahtani,
Anne O'Dea,
Hope Rugo,
Mark Pegram,
Lauren Carcas,
Chirag Shah,
Frank Vicini,
Thomas Buchholz
- 164 views
- November 30, 2023
- 1
PrecisCa
Meta-Analysis of 16,500 Women With Early Stage BC in 13 Randomized Trials: Using of Anthracyclines in the Adjuvant Setting
FEATURING
Mark Pegram
- 193 views
- August 18, 2023
- 3
PrecisCa
What Is Trastuzumab-Deruxtecan and What Should I Know When I'm Giving It
FEATURING
Lake Littlejohn
- 72 views
- August 18, 2023
- 1
PrecisCa
Different Types of Molecular Testing and Why Are They Done
FEATURING
Lake Littlejohn
- 89 views
- August 18, 2023
- 1
PrecisCa
Managing Common Toxicities From CDK4/6i
FEATURING
Erin Shonkwiler
- 140 views
- August 18, 2023
- 1
PrecisCa
Expert Case Discussion: 68 y/o With HR+/HER2- mBC With Progression to TNBC
- 163 views
- August 18, 2023
- 2
PrecisCa
Omitting Radiotherapy Following Breast Conserving Surgery in Low Risk, HR+ Breast Cancer: The LUMINA trial
FEATURING
Reshma L. Mahtani
- 378 views
- June 17, 2023
- 3
PrecisCa
Treatment of Oligometastatic Disease in Breast Cancer
FEATURING
Reshma L. Mahtani
- 46 views
- June 17, 2023
PrecisCa
Advanced Breast Cancer Updates: Continuation of Ribociclib After Progression on CDK4/6i
FEATURING
Reshma L. Mahtani
- 30 views
- June 17, 2023
PrecisCa
Overall Survival Data for Palbociclib in the PALOMA-2 Trial for HR+/HER2- aBC
FEATURING
Reshma L. Mahtani
- 75 views
- June 17, 2023
- 1
PrecisCa
Use of Capivasertib in Relapsed/Refractory HR+ Breast Cancer
FEATURING
Reshma L. Mahtani
- 86 views
- June 17, 2023
- 2
PrecisCa
How to Optimally Utilize Trastuzumab Deruxtecan for HER2+ mBC
FEATURING
Joyce O'Shaughnessy
- 248 views
- September 14, 2022
PrecisCa
Current Approach to mTNBC Treatment
FEATURING
Sara A. Hurvitz
- 1,084 views
- September 14, 2022
- 2
PrecisCa
Treatment of Metastatic HER2+ BC With Organ Dysfunction Through Various Lines of Therapy
FEATURING
Sara A. Hurvitz
- 33 views
- September 14, 2022
PrecisCa
Omitting Radiation Therapy After Lumpectomy for Patients With EBC: Factors to Consider
FEATURING
Thomas Buchholz
- 796 views
- September 14, 2022
- 7
